Search Results - "van Bueren, Jeroen J Lammerts"

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma by Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI

“…Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1…”
Get full text

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage by Schneider-Merck, Tanja, Lammerts van Bueren, Jeroen J, Berger, Sven, Rossen, Kai, van Berkel, Patrick H.C, Derer, Stefanie, Beyer, Thomas, Lohse, Stefan, Bleeker, Wim K, Peipp, Matthias, Parren, Paul W. H. I, van de Winkel, Jan G. J, Valerius, Thomas, Dechant, Michael

“…Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of action for immunotherapy with human IgG1 but not IgG2 Abs. The…”
Get full text

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond by van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.

“…Summary CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on…”
Get full text

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy by Oostendorp, Marlies, Lammerts van Bueren, Jeroen J., Doshi, Parul, Khan, Imran, Ahmadi, Tahamtan, Parren, Paul W.H.I., van Solinge, Wouter W., De Vooght, Karen M.K.

“…BACKGROUND Monoclonal antibodies (MoAbs) are increasingly integrated in the standard of care. The notion that therapeutic MoAbs can interfere with clinical…”
Get full text

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma by Drent, Esther, Groen, Richard W J, Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna

“…Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression…”
Get full text

antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility by Lammerts van Bueren, Jeroen J, Bleeker, Wim K, Brännström, Annika, von Euler, Anne, Jansson, Magnus, Peipp, Matthias, Schneider-Merck, Tanja, Valerius, Thomas, van de Winkel, Jan G.J, Parren, Paul W.H.I

“…The epidermal growth factor receptor (EGFR) activates cellular pathways controlling cell proliferation, differentiation, migration, and survival. It thus…”
Get full text

Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII) by Klausz, Katja, Berger, Sven, Lammerts van Bueren, Jeroen J., Derer, Stefanie, Lohse, Stefan, Dechant, Michael, van de Winkel, Jan G. J., Peipp, Matthias, Parren, Paul W. H. I., Valerius, Thomas

“…Monoclonal antibodies (mAb) against variant III of epidermal growth factor receptor (EGFRvIII) hold promise for improving tumor selectivity of EGFR‐targeted…”
Get full text

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells by Peipp, Matthias, Lammerts van Bueren, Jeroen J., Schneider-Merck, Tanja, Bleeker, Wim W.K., Dechant, Michael, Beyer, Thomas, Repp, Roland, van Berkel, Patrick H.C., Vink, Tom, van de Winkel, Jan G.J., Parren, Paul W.H.I., Valerius, Thomas

“…Glycosylation of the antibody Fc fragment is essential for Fc receptor–mediated activity. Carbohydrate heterogeneity is known to modulate the activity of…”
Get full text

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies by DECHANT, Michael, WEISNER, Wencke, VALERIUS, Thomas, BERGER, Sven, PEIPP, Matthias, BEYER, Thomas, SCHNEIDER-MERCK, Tanja, LAMMERTS VAN BUEREN, Jeroen J, BLEEKER, Wim K, PARREN, Paul W. H. I, VAN DE WINKEL, Jan G. J

“…Therapeutic monoclonal antibodies against the epidermal growth factor receptor (EGFR) have advanced the treatment of colon and head and neck cancer, and show…”
Get full text

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking by Overdijk, Marije B, Jansen, J H Marco, Nederend, Maaike, Lammerts van Bueren, Jeroen J, Groen, Richard W J, Parren, Paul W H I, Leusen, Jeanette H W, Boross, Peter

“…Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic…”
Get full text

Systematic study of tissue factor expression in solid tumors by Bono, Johann S., Harris, Jeffrey R., Burm, Saskia M., Vanderstichele, Adriaan, Houtkamp, Mischa A., Aarass, Saida, Riisnaes, Ruth, Figueiredo, Ines, Nava Rodrigues, Daniel, Christova, Rossitza, Olbrecht, Siel, Niessen, Hans W. M., Ruuls, Sigrid R., Schuurhuis, Danita H., Lammerts van Bueren, Jeroen J., Breij, Esther C. W., Vergote, Ignace

“…Background Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been…”
Get full text

Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor : Implications for the mechanisms of action by LAMMERTS VAN BUEREN, Jeroen J, BLEEKER, Wim K, BOGH, Henrik O, HOUTKAMP, Mischa, SCHUURMAN, Janine, VAN DE WINKEL, Jan G. J, PARREN, Paul W. H. I

“…The epidermal growth factor receptor (EGFR) is overexpressed on many solid tumors and represents an attractive target for antibody therapy. Here, we describe…”
Get full text

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements by Schram, Alison M, Odintsov, Igor, Espinosa-Cotton, Madelyn, Khodos, Inna, Sisso, Whitney J, Mattar, Marissa S, Lui, Allan J W, Vojnic, Morana, Shameem, Sara H, Chauhan, Thrusha, Torrisi, Jean, Ford, Jim, O'Connor, Marie N, Geuijen, Cecile A W, Schackmann, Ron C J, Lammerts van Bueren, Jeroen J, Wasserman, Ernesto, de Stanchina, Elisa, O'Reilly, Eileen M, Ladanyi, Marc, Drilon, Alexander, Somwar, Romel

“…NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased…”
Get more information

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide by Nijhof, Inger S, Lammerts van Bueren, Jeroen J, van Kessel, Berris, Andre, Pascale, Morel, Yannis, Lokhorst, Henk M, van de Donk, Niels W C J, Parren, Paul W H I, Mutis, Tuna

“…Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important…”
Get full text

Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression by Derer, Stefanie, Berger, Sven, Schlaeth, Martin, Schneider-Merck, Tanja, Klausz, Katja, Lohse, Stefan, Overdijk, Marije B, Dechant, Michael, Kellner, Christian, Nagelmeier, Iris, Scheel, Andreas H, Lammerts van Bueren, Jeroen J, van de Winkel, Jan G.J, Parren, Paul W.H.I, Peipp, Matthias, Valerius, Thomas

“…Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab)…”
Get full text

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains by Parren, Paul W H I, van Bueren, Jeroen J Lammerts, Rispens, Theo, Verploegen, Sandra, van der Palen-Merkus, Tjitske, Turinsky, Andrei L, Stapel, Steven, Workman, Lisa J, James, Hayley, van Berkel, Patrick H C, van de Winkel, Jan G J, Platts-Mills, Thomas A E

Get full text

Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition by Overdijk, Marije B, Verploegen, Sandra, van den Brakel, Jeroen H, Lammerts van Bueren, Jeroen J, Vink, Tom, van de Winkel, Jan G J, Parren, Paul W H I, Bleeker, Wim K

“…Ab-dependent cellular cytotoxicity (ADCC) is recognized as a prominent cytotoxic mechanism for therapeutic mAbs in vitro. However, the contribution of ADCC to…”
Get full text

Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy by Bleeker, Wim K, Lammerts van Bueren, Jeroen J, van Ojik, Heidi H, Gerritsen, Arnout F, Pluyter, Marielle, Houtkamp, Mischa, Halk, Ed, Goldstein, Joel, Schuurman, Janine, van Dijk, Marc A, van de Winkel, Jan G. J, Parren, Paul W. H. I

“…Epidermal growth factor receptor (EGF-R) overexpression is common in a large number of solid tumors and represents a negative prognostic indicator…”
Get full text

Novel human antibody therapeutics: The age of the Umabs by Ruuls, Sigrid R., Lammerts van Bueren, Jeroen J., van de Winkel, Jan G. J., Parren, Paul W. H. I.

“…Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human diseases. The state‐of‐the‐art…”
Get full text

Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations by Peipp, Matthias, Schneider-Merck, Tanja, Dechant, Michael, Beyer, Thomas, Lammerts van Bueren, Jeroen J, Bleeker, Wim K, Parren, Paul W. H. I, van de Winkel, Jan G. J, Valerius, Thomas

“…The epidermal growth factor receptor (EGFR) serves as a molecular target for novel cancer therapeutics such as tyrosine kinase inhibitors (TKI) and EGFR Abs…”
Get full text